Market Place
Sourcing Support
TRACON Pharmaceuticals Announces it Will Wind Down Operations
30 Jul 2024 //
GLOBENEWSWIRE
China-made injectable PD-L1 drug flunks pivotal trial
02 Jul 2024 //
FIERCE PHARMA
TRACON Ends ENVASARC Trial, Explores Strategic Alternatives
01 Jul 2024 //
GLOBENEWSWIRE
TRACON Pharma Reports Q1 2024 Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
TRACON Q1 2024 Results and Update on May 14
06 May 2024 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces Reverse Stock Split
08 Apr 2024 //
GLOBENEWSWIRE
TRACON Update on Ongoing ENVASARC Ph 2 Trial
03 Apr 2024 //
GLOBENEWSWIRE
TRACON Reports Fourth Quarter and Year-End 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
TRACON Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
20 Dec 2023 //
GLOBENEWSWIRE
TRACON Announces License of Development Platform for $3.0M Upfront Payment
20 Nov 2023 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
TRACON to Report Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
TRACON Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold
18 Sep 2023 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
TRACON to Report Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
TRACON Pharma Announces Positive Results Based on Ongoing Double-Digit Objective
20 Jun 2023 //
GLOBENEWSWIRE
TRACON Pharmaceuticals to Present at the Maxim Group Virtual Conference
16 Jun 2023 //
GLOBENEWSWIRE
TRACON Announces Enforcement Action to Collect Binding Arbitration
15 Jun 2023 //
GLOBENEWSWIRE
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
TRACON Announces Poster Presentations for Envafolimab and TRC102
30 May 2023 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Reports 1Q 2023 FYR and Provides Corporate Update
10 May 2023 //
GLOBENEWSWIRE
TRACON to Report 1Q 2023 Financial Results and Provide Corporate Update
03 May 2023 //
GLOBENEWSWIRE
I-Mab Announces Outcome in Arbitration Relating to Agreements with Tracon
25 Apr 2023 //
PR NEWSWIRE
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
25 Apr 2023 //
GLOBENEWSWIRE
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing
27 Dec 2022 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces Positive Results from the ENVASARC PhII Trial
14 Dec 2022 //
GLOBENEWSWIRE
TRACON Announces Dosing of First Patient in Phase 1/2 Trial of YH001
21 Nov 2022 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring
06 Oct 2022 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing
06 Sep 2022 //
GLOBENEWSWIRE
Biocytogen and Tracon get FDA IND clearance for Phase I/II sarcoma trial
30 Aug 2022 //
CLINICALTRIALSARENA
TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001
29 Aug 2022 //
GLOBENEWSWIRE
TRACON Pharma Announces Results of Independent Data Monitoring Committee Review
10 Aug 2022 //
GLOBENEWSWIRE
TRACON Pharma Reports Q2 Financial Results & Provides Corporate Update
10 Aug 2022 //
GLOBENEWSWIRE
TRACON Pharma Submits IND Application for CTLA-4 Antibody YH001
08 Aug 2022 //
GLOBENEWSWIRE
TRACON to Report Second Quarter 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
TRACON Pharma Announces Dosing of 36th Patient in ENVASARC Pivotal Trial
26 Jul 2022 //
GLOBENEWSWIRE
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
TRACON Pharmaceuticals to Present at the H.C. Wainwright Conference
16 May 2022 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
TRACON to Report First Quarter 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
TRACON Pharma Announces Amended ENVASARC Protocol Approved and Open
19 Apr 2022 //
GLOBENEWSWIRE
TRACON Pharma to Present at the Maxim Group 2022 Virtual Growth Conference
23 Mar 2022 //
GLOBENEWSWIRE
TRACON Pharma Reports Q4 and Year-End 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
TRACON to Present at the Oppenheimer 32nd Annual Healthcare Conference
11 Mar 2022 //
GLOBENEWSWIRE
TRACON Pharma says FDA Approval of Amended ENVASARC Protocol
10 Mar 2022 //
GLOBENEWSWIRE
TRACON to Report Q4 and Full Year 2021 Financial Results on March 15
04 Mar 2022 //
GLOBENEWSWIRE
TRACON Announces Positive Results from IDMC Review from Ongoing ENVASARC Trial
27 Dec 2021 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China
29 Nov 2021 //
GLOBENEWSWIRE
TRACON to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
13 Sep 2021 //
GLOBENEWSWIRE
TRACON second 2021 Financial Results and Company Highlights on August 11, 2021
28 Jul 2021 //
GLOBENEWSWIRE
TRACON Pharmaceuticals $10 Million Bought Deal Offering of Common Stock
21 Jul 2021 //
GLOBENEWSWIRE
TRACON Pharmaceuticals $10 Million Bought Deal Offering of Common Stock
21 Jul 2021 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces Appointment of Ya Huang
30 Jun 2021 //
GLOBENEWSWIRE
TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab
29 Jun 2021 //
GLOBENEWSWIRE
TRACON Pharma Announces Poster Presentations at the ASCO Virtual Annual Meeting
20 May 2021 //
GLOBENEWSWIRE
TRACON Pharma Appoints Dongliang Zhuang as VP of Statistics and Biometrics
04 May 2021 //
GLOBENEWSWIRE
